Rivastigmine Liquid
NDC Package 65841-184-07

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Rivastigmine liquids is rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. This formulation utilizes a liquid delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 65841-184.

Identification & Billing

NDC Package Code
65841-184-07
Package Description
2 kg in 1 BOTTLE, GLASS
Product Code
65841-184
11-Digit Billing Format
65841018407

Clinical Specifications

Proprietary Name
Rivastigmine
Non-Proprietary Name
Rivastigmine
Substance Name
Rivastigmine
Dosage Form
Liquid - A dosage form consisting of a pure chemical in its liquid1 state. This dosage form term should not be applied to solutions.
Active Ingredient(s)
RIVASTIGMINE 1 kg/kg
Usage Information
Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

Regulatory & Marketing

Labeler Name
Zydus Lifesciences Limited
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
12-24-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 65841-184-07 identifies a specific commercial package of 2 kg in 1 bottle, glass of Rivastigmine (UNFINISHED drug), a bulk ingredient labeled by Zydus Lifesciences Limited. This liquid is formulated for use and contains rivastigmine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on December 24, 2024. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

How is this Zydus Lifesciences Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 65841018407. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
65841-184-07
11-Digit CMS (5-4-2)
65841-0184-07

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.